In addition to the clinical and patient reported outcomes data analysis, assessing the economic burden of liver disease or performing cost-effectiveness analysis of different treatment regimens or management strategies are of great importance to fully assess the comprehensive impact of liver disease. Members of COR-LD have been leaders in this field. The team has performed some of the earliest economic analysis of HCV and HCV treatment. Furthermore, the COR-LD team has been the first to economic impact of NAFLD, NASH and HBV. Additional analysis includes cholestatic liver disease, complications of cirrhosis and other liver diseases. The team uses both Markov Model-decision models and other techniques to estimate the economic burden, cost-effectiveness of treatment or screening strategies and cost of illness for different liver diseases. Furthermore, the team uses extensive administrative databases with payer data (Medicare, National Inpatient Sample, Medical Expenditure Panel Survey) to assess the economic burden of different liver diseases in different healthcare settings. Member of COR-LD have also pioneered strategies to combine clinical, PRO and economic outcomes to provide comprehensive assessments and estimate the full value of different treatment strategies in liver disease.
